3 Boomerang Capital's Portfolio Company Taps Accomplished Life Sciences Leader to Drive Next Phase of Growth, Further Strengthening Research & Discovery for Biotech & Pharma Developers
NEW CASTLE, Del. and GREENWICH, Conn., July 9, 2025 /PRNewswire/ -- ABS Bio, Inc., ("ABS Bio" or "the Company"), a 3 Boomerang Capital ("3 Boomerang" or "3BC") portfolio company and a leader in biospecimen sourcing, cell culture services, and biorepository solutions for the global pharmaceutical and biotechnology industry, today announced the appointment of Ehab Alramahy as President and Chief Executive Officer. Company founder Charles Saller, Ph.D., will step down from day-to-day leadership but continue serving on the Board of Directors.
Mr. Alramahy is a seasoned executive with a strong track record of driving commercial growth, building high-performing teams, and leading complex life science businesses across North America and Europe. He brings a powerful mix of scientific insight and strategic leadership, having previously led global divisions at BioIVT, Biosynth Group, and Bachem Group. His blend of hands-on technical experience and executive leadership uniquely positions him to guide ABS Bio's next phase of growth.
"ABS Bio and 3 Boomerang Capital are thrilled to welcome Ehab Alramahy to this important role," said John Chickosky, Executive Chairman of ABS Bio. "In our search for a successor, we prioritized deep domain expertise and a leadership style that reflects ABS Bio's client-first culture. Ehab brings both to the table, and we are confident he will earn the trust of our team and our clients from day one."
"I am honored to lead ABS Bio and excited to work alongside John, the Board, and the talented team to drive the Company forward," said Ehab Alramahy, President and CEO of ABS Bio. "I am especially grateful to Charlie Saller for building such an exceptional organization and for remaining on the board to share his experience and counsel. ABS Bio has built a reputation for reliability and scientific excellence, and I look forward to expanding our impact across the biopharma industry."
"ABS Bio has earned its place as a trusted partner to nearly all major pharma companies," said Charles Saller. "Ehab's experience, energy, and deep understanding of the scientific capabilities that make ABS Bio unique give me great confidence in the Company's future."
About ABS Bio
Founded in 1990, ABS Bio has made research and discovery faster, easier, and more reliable for pharmaceutical and biotech developers. With a suite of custom services—including biospecimen sourcing, cell culture, and integrated biostorage—ABS Bio enables research teams to focus on core objectives while ensuring mission-critical functions are fulfilled with precision and quality. Based in New Castle, DE, ABS Bio is distinguished by consistently high satisfaction ratings from clients ranging from large pharma to emerging biotech. For more information, visit ABSBio.com.
About 3 Boomerang Capital
3 Boomerang Capital is a lower middle market healthcare private equity firm committed to fostering creative investment partnerships with healthcare entrepreneurs across North America and Western Europe. 3BC's areas of investment focus span four key healthcare sectors: Biopharma outsourcing, medical device and diagnostic manufacturing, information technology and tech-enabled services, and alternate site care. The firm specializes in backing founder-led businesses, providing the guidance and resources needed for successful growth and innovation in the healthcare market. By strategically concentrating on four core areas, 3 Boomerang Capital is well-equipped to deliver on its mission of empowering healthcare entrepreneurs and propelling healthcare businesses to new heights. The firm is currently investing out of its flagship fund, 3 Boomerang Capital I, LP, a $376 million investment vehicle.
For more information, visit https://www.3boomerang.com/
Media Contact
Laura Simpson
JConnelly for 3 Boomerang Capital
[email protected]
SOURCE 3 Boomerang Capital; ABS Bio
Share this article